Edwards Lifesciences still has positive catalysts over longer term, says Stifel After Edwards Lifesciences provided weaker than expected FY14 EPS guidance, Stifel thinks the company's growth rates could return to above average levels in 2015 and beyond The firm expects the company to benefit from strong growth of the TAVR market over the longer term and it keeps a Buy rating on the shares.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences upgraded to Outperform from Market Perform at Wells Fargo Wells Fargo upgraded Edwards Lifesciences citing a number of positive developments since it downgraded the stock in December 2013, including strong Q4 Sapien results outside the U.S. and the company's successful first-inman transcatheter mitral valve implants. Wells raised its price target range for shares to $82-$83 from $67-$69.